April 26, 2018
Shares of Axsome increased nearly 20 percent after the announcement, but evened out to an overall 13.21-percent increase to $3.
April 19, 2018
Flexion Therapeutics (Nasdaq:FLXN) today announced that the key results from the previously completed pivotal Phase 3 study evaluating ZILRETTA (triamcinolone...
April 9, 2018
CBD is improving health and driving the cannabis industry. Know more about its health benefits and opportunities for CBD-based companies.
March 20, 2018
The company has released positive Phase 2B clinical trial results for its lead drug. The study was to evaluate the...
March 16, 2018
Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies...
June 21, 2017
A paper co-authored by Kristin Comella's, chief science officer for U.S. Stem Cell about an intra-articular injection for the treatment...
April 7, 2017
Flexion Therapeutics (NASDAQ: FLXN) appointed Dr. Yamo Deniz as its new Chief Medical Officer.